Related Articles
Study Finds Tocilizumab Could Be Treatment Option for Takayasu Arteritis
For patients with refractory Takayasu arteritis (TAK), glucocorticoids (GCs) are often provided as the initial therapy for treatment. However, GCs are often associated with adverse effects for long-term use; relapse also occurs frequently during GC tapering.1 TAK involves interleukin (IL) 6. Tocilizumab—a recombinant, humanized, anti-IL-6 receptor (IL-6R) monoclonal antibody—was first reported by Nishimoto et al….
Fellow’s Forum Case Report: Takayasu’s Arteritis
How this rare form of large-vessel vasculitis affects different portions, branches of aorta and ways to diagnose, treat and manage the disease
Is B a Key to Autoimmune Therapy?: B Cell–targeted Therapies in Autoimmune Disease
A perspective on B cell–targeted therapies in autoimmune disease
Patients with Large-Vessel Abnormalities Present Diagnostic Dilemma for Rheumatologists
Absent signs, symptoms suggesting etiology, clinicians rely on inflammatory markers, imaging to make the diagnosis